Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
08 Oct 2016 ESMO 2016: Factors Identified That Associate with Near the End of Life Chemotherapy Use Palliative and supportive care
08 Oct 2016 ESMO 2016: Antitumour Activity Demonstrated With Lurbinectedin in Patients With Metastatic Breast Cancer and BRCA Mutations Breast cancer - Anticancer agents & Biologic therapy
08 Oct 2016 ESMO 2016: Trabectedin Improves PFS Over Best Supportive Care in Patients with Pretreated Advanced Soft Tissue Sarcoma Sarcomas - Anticancer agents & Biologic therapy
08 Oct 2016 ESMO 2016 Press Release: Phase I Study of Novel Anti-Cancer Drug Uses Tumour mRNA Expression to Identify Responders Anticancer agents & Biologic therapy
08 Oct 2016 ESMO 2016 Press Release: Immunotherapy Shows Promising Results in First and Second Line Treatment of Metastatic Bladder Cancer Genitourinary cancers - Anticancer agents & Biologic therapy
08 Oct 2016 ESMO 2016 Press Release: Targeting Estrogen Receptor Improves Progression-free Survival in Advanced Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
07 Oct 2016 ESMO 2016 Press Release: Thousands of Melanoma Patients in Europe Have no Access to New Life Saving Drugs Melanoma
07 Oct 2016 ESMO 2016 Press Release: Neoadjuvant Immunotherapy Prior to Surgery is Safe and Feasible in Early Lung Cancer Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
29 Sep 2016 FDA Modifies the Dosage Regimen for Currently Approved Indications for Nivolumab Genitourinary cancers - Melanoma - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
28 Sep 2016 EU-US collaboration to boost medicine development for rare diseases Bioethics, legal and economic issues
27 Sep 2016 NICE Releases a Quality Standard in Skin Cancer Melanoma
22 Sep 2016 EMA Recommends Granting a Marketing Authorisation for Edotreotide Imaging - Endocrine cancers
21 Sep 2016 EMA Recommends Granting a Conditional Marketing Authorisation for Ixazomib Haematologic malignancies - Anticancer agents & Biologic therapy
20 Sep 2016 EMA Recommends Granting a Conditional Marketing Authorisation for Olaratumab Sarcomas - Anticancer agents & Biologic therapy
19 Sep 2016 Press Release: Launch of First eUpdate Integrating Breakthroughs in ESMO Clinical Practice Guidelines